Can THEM6 targeting stop resistance to prostate cancer treatment?

Mrittika Chattopadhyay, Doris Germain

Research output: Contribution to journalComment/debate


Prostate cancer (PCa) clinical management relies heavily on androgen-deprivation therapy (ADT). However, despite experiencing initial clinical benefit, patients getting ADT for non-resectable PCa eventually relapse and develop fatal castration-resistant PCa (CRPC). Multiple mechanisms of acquired resistance to treatment have been reported, including metabolic adaptation (Marine et al, 2020). Notably, activation of the endoplasmic reticulum (ER) unfolded protein response (UPR) has been associated with oncogenic transformation (Hart et al, 2012), tumor progression, metastasis dissemination, and resistance to therapy (Chen & Cubillos-Ruiz, 2021). Targeting different branches of ER UPR has been found to be an effective tool against aggressive PCa (Nguyen et al, 2018; Sheng et al, 2019). Therefore, a better understanding of these pathways may lead to the identification of novel drug targets.

Original languageEnglish
Article numbere15504
JournalEMBO Molecular Medicine
Issue number3
StatePublished - 7 Mar 2022


Dive into the research topics of 'Can THEM6 targeting stop resistance to prostate cancer treatment?'. Together they form a unique fingerprint.

Cite this